Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in mycobacterium tuberculosis

Microbial Drug Resistance

Volumn 18, Issue 2, 2012, Pages 193-197

  Sirgel, Frederick A ^a   Tait, Marisa ^a   Warren, Robin M ^a   Streicher, Elizabeth M ^a   Böttger, Erik C ^b   Van Helden, Paul D ^a   Gey Van Pittius, Nicolaas C ^a   Coetzee, Gerrit ^c   Hoosain, Ebrahim Y ^d   Chabula Nxiweni, Mamisa ^d   Hayes, Cindy ^c   Victor, Thomas C ^a   Trollip, André ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d Nelson Mandela Bay Municipality   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ALANINE; AMIKACIN; BACTERIAL DNA; BACTERIAL PROTEIN; CAPREOMYCIN; GLYCINE; MIDDLEBROOK 7H11 AGAR; PROTEIN RRS; TLYA PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; DRUG BIOAVAILABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SOUTH AFRICA; WILD TYPE;

AMIKACIN; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CAPREOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84859568104     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2011.0063     Document Type: Article

References (24)

1. Alangadan, G.J., B.N. Kreiswirth, A. Aouad, M. Khetarpal, F.R. Igno, S.L. Moghazeh, E.K. Manavathu, and S.A. Lerner. 1998. Mechanisms of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 42:1295-1297. (Pubitemid 28227943)
2. Anonymous. 2008. Capreomycin. Tuberculosis 88:89-91.
3. Chan, E.D., and M.D. Iseman. 2008. Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Curr. Opin. Infect. Dis. 21:587-595.
4. Engstroöm, A., N. Perskvist, J. Werngren, S.V. Hoffner, and P. Juréen. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247-1254.
5. Feuerriegel S., H.S. Cox, N. Zarkua, H.A. Karimovich, K. Braker, S. Ruösch-Gerdes, and Stefan Niemann. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob. Agents Chemother. 53:3353-3356.
6. Gandhi, N.L., A. Moll, A.W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
7. Heifets, L., and E. Desmond. 2005. Clinical mycobacteriology (tuberculosis) laboratory: Services and methods. In S.T. Cole, K.D. Eisenach, D.N. Murray, and W.J. Jacobs, Jr. (eds.), Tuberculosis and the Tubercle Bacillus. American Society for Microbiology, Washington, DC, pp. 49-70.
8. Heifets, L., J. Simon, and V. Pham. 2005. Capreomycin is active against non-replicating M. tuberculosis. Ann. Clin. Microbiol. Antimicrob. 4:6.
9. Johansen, S., C.E. Maus, B.B. Plikaytis, and S. Douthwaite. 2006. Capreomycin binds across the ribosome subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. Mol. Cell 23:173-182. (Pubitemid 44081881)
10. Jugheli, L., N. Bzekalava, P. de Rijk, K. Fisette, F. Portaels, and L. Rigouts. 2009. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob. Agents Chemother. 53:5064-5068.
11. Juréen, P., K. Aöngeby, E. Sturegård, E. Chryssanthou, C.G. Giske, J. Werngren, M. Nordvall, A. Johansson, G. Kahlmeter, S. Hoffner, and T. Schoön. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J. Clin. Microbiol. 48:1853-1858.
12. Maus, C.E., B.B. Plikaytis, and T.M. Shinnick. 2005. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197. (Pubitemid 41060560)
13. Maus, C.E., B.B. Plikaytis, and T.M. Shinnick. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:571-577. (Pubitemid 40175664)
14. Migliori, G.B., C. Lange, R. Centis, G. Sotgiu, R. Muötterlein, H. Hoffmann, K. Kliiman, G. De Iaco, F.N. Lauria, M.D. Richardson, A. Spanevello, D.M. Cirillo, and TBNET Study Group. 2008. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drugresistant tuberculosis cases. Eur. Respir. J. 31:1155-1159.
15. Rozen, S., and H.J. Skaletsky. 2009. Primer3 on the WWW for general users and for biologist programmers. (v. 0.40) pick primers from a DNA sequence. Available at http://frodo.wi.mit.edu/primer3/. (Online.
16. Sander, P., T. Prammananan, and E.C. Boöttger. 1996. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol. Microbiol. 22:841-848. (Pubitemid 26411329)
17. Sandgren A., M. Strong, P. Muthukrishnan, B.K. Weiner, G.M. Church, and M.B. Murray. 2009. Tuberculosis drug resistance mutation database. PloS Med. 6:e2.
18. Schoön, T., P. Juréen, C.G. Giske, E. Chryssanthou, E. Sturegård, J. Werngren, G. Kahlmeter, S.E. Hoffner, and K.A. Aöngeby. 2009. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:786-793.
19. Shcherbakov, D., R. Akbergenov, T. Matt, P. Sander, D.I. Anderson, and E.C. Boöttger. 2010. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol. Microbiol. 77:830-840.
20. Springer, B., K. Lucke, C. Calligaris-Maibach, C. Ritter, and E.C. Boöttger. 2009. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter Instrumentation. J. Clin. Microbiol. 47:1773-1780.
21. Van Ingen, J., S. Simons, R. de Zwaan, T. van der Laan, M. Kampst-van Agterveld, and M.J. Boeree. 2010. Comparative study on genotypic and phenotypic second-line drug resistant testing of Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:2749-2753.
22. Via, L.E., S.-N. Cho, S. Hwang, H. Bang, S.K. Park, H.S. Kang, et al. 2010. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J. Clin. Microbiol. 48:402-411.
23. World Health Organization (WHO). 2008. Treatment strategies for MDR-TB. In Guidelines for the Programmatic Managament of Drug-Resistant Tuberculosis (WHO):50-74. (WHO/HTM/TB/2008.402). WHO, Geneva, Switzerland.
24. World Health Organization (WHO). 2008. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Report (WHO/HTM/TB/2008.392):1-WHO, Geneva, Switzerland.